tetano
Editor, Senior Moderator
Expert Opin Drug Discov. 2015 Jan 13:1-6. [Epub ahead of print]
[h=1]Vaccines 'on demand': science fiction or a future reality.[/h] Ulmer JB[SUP]1[/SUP], Mansoura MK, Geall AJ.
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Self-amplifying mRNA vaccines are being developed as a platform technology with potential to be used for a broad range of targets. The synthetic production methods for their manufacture, combined with the modern tools of bioinformatics and synthetic biology, enable these vaccines to be produced rapidly from an electronic gene sequence. Preclinical proof of concept has so far been achieved for influenza, respiratory syncytial virus, rabies, Ebola, cytomegalovirus, human immunodeficiency virus and malaria. Areas covered: This editorial highlights the key milestones in the discovery and development of self-amplifying mRNA vaccines, and reviews how they might be used as a rapid response platform. The paper points out how future improvements in RNA vector design and non-viral delivery may lead to decreases in effective dose and increases in production capacity. Expert opinion: The prospects for non-viral delivery of self-amplifying mRNA vaccines are very promising. Like other types of nucleic acid vaccines, these vaccines have the potential to draw on the positive attributes of live-attenuated vaccines while obviating many potential safety limitations. Hence, this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather than the deployment of strategic stockpiles based on epidemiological predictions for possible threats.
[h=4]KEYWORDS:[/h] pandemic; rapid response; synthetic; vaccines
PMID: 25582273 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25582273
[h=1]Vaccines 'on demand': science fiction or a future reality.[/h] Ulmer JB[SUP]1[/SUP], Mansoura MK, Geall AJ.
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Self-amplifying mRNA vaccines are being developed as a platform technology with potential to be used for a broad range of targets. The synthetic production methods for their manufacture, combined with the modern tools of bioinformatics and synthetic biology, enable these vaccines to be produced rapidly from an electronic gene sequence. Preclinical proof of concept has so far been achieved for influenza, respiratory syncytial virus, rabies, Ebola, cytomegalovirus, human immunodeficiency virus and malaria. Areas covered: This editorial highlights the key milestones in the discovery and development of self-amplifying mRNA vaccines, and reviews how they might be used as a rapid response platform. The paper points out how future improvements in RNA vector design and non-viral delivery may lead to decreases in effective dose and increases in production capacity. Expert opinion: The prospects for non-viral delivery of self-amplifying mRNA vaccines are very promising. Like other types of nucleic acid vaccines, these vaccines have the potential to draw on the positive attributes of live-attenuated vaccines while obviating many potential safety limitations. Hence, this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather than the deployment of strategic stockpiles based on epidemiological predictions for possible threats.
[h=4]KEYWORDS:[/h] pandemic; rapid response; synthetic; vaccines
PMID: 25582273 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25582273